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Abstract
This review takes a sceptical view of the impact of breast cancer
studies that have used microarrays to identify predictors of clinical
outcome. In addition to discussing general pitfalls of microarray
experiments, we also critically review the key breast cancer studies
to highlight methodological problems in cohort selection, statistical
analysis, validation of results and reporting of raw data. We
conclude that the optimum use of microarrays in clinical studies
requires further optimisation and standardisation of methodology
and reporting, together with improvements in clinical study design.
Introduction
By the time that a breast cancer is clinically apparent it has
undergone multiple genetic and epigenetic primary carcino-
genic events and further secondary molecular changes that
ensure the adaptation of its cells to the changing micro-
environment. The diversity of these genetic changes has
made it difficult to classify breast cancer molecularly, and as a
consequence there has been great enthusiasm for using
genome-wide profiling methods to acquire a better
understanding of the disease. This has led to an increasing
number of studies using expression array profiling to improve
the prediction of cancer prognosis [1–7]. Great things have
been promised by exponents of these technologies [8]. How
should we view the impact of current work?
Microarray technology
Irrespective of the questions being addressed in a profiling
study, microarray techniques have inherent problems that
lead to considerable data variability. Major sources of
variability can arise from methods of RNA extraction [9,10],
different types of probe preparation [9,11], probe labelling
[12,13] and hybridisation [14,15]. It is also clear that varying
the microarray platform, reference sample or segmentation
method used for microarray image analysis leads to significant
differences in data repeatability and gene discovery [16-18].
Although the MIAME (minimum information about a
microarray experiment) report defines standards for infor-
mation needed for reporting microarray experiments [19], it
does not describe or quantify variabilities in the experiments.
More studies addressing these experimental issues are
urgently needed [20,21] along with efforts to define common
standards for expression measurement controls. Guidelines
are already emerging for best practice in using expression
profiling for clinical trials [22].
The aim of supervised classification of microarray data is to
detect genes that might prospectively predict defined
outcomes. Existing studies in breast cancer have involved
three steps: identifying a set of genes that are different
between survival or drug response, refining this set for optimal
classification within the sample set and finally validating the
performance of the classifier genes on independent samples.
Several studies have addressed these questions [1–7], but
even before examining the technology a critical appraisal of
the studies shows multiple methodological problems that
make the interpretation of the results difficult.
Clinical study design
The problems can be summarised into four main categories:
cohort selection, statistical analysis, validation of results and
reporting of raw data. With the exception of the report by
Chang and colleagues [5], studies were conducted as
retrospective analyses of ‘available’ samples. Data collected
retrospectively are inevitably incomplete, posing a complex
problem in the interpretation of results [23,24]. Lack of
detailed clinical information from paper records often means
that important clinical predictors cannot be included in
multivariate analysis to estimate the true predictive values of
novel classifiers. This is exemplified by the studies from Ahr
and colleagues [4] and van ’t Veer and colleagues [2] that
examined the association between a microarray classifier and
prognosis without accounting for the effects of important
clinical parameters such as performance status or treatment
Commentary
Microarrays and breast cancer clinical studies: forgetting what
we have not yet learnt
Ahmed Ashour Ahmed and James D Brenton
Cancer Genomics Programme, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK
Corresponding author: James D Brenton, jdb1003@cam.ac.uk
Published: 1 April 2005 Breast Cancer Research 2005, 7:96-99 (DOI 10.1186/bcr1017)
This article is online at http://breast-cancer-research.com/content/7/3/96
© 2005 BioMed Central Ltd
See related commentary by Chang et al., page 100 [http://breast-cancer-research.com/content/7/3/100]97
Available online http://breast-cancer-research.com/contents/7/3/96
modality. The use of ‘available’ samples may introduce
significant heterogeneity into patient characteristics and
unexpected temporal effects. van de Vijver and colleagues [3]
used a ‘validation set’ (see below) containing patients treated
with different modalities of surgery, chemotherapy and
radiotherapy over 11 years. Each of these variables could
introduce significant prognostic differences and make the
estimation of the true independent effect of a molecular
classifier difficult. A multi-variable analysis of data from van de
Vijver and colleagues [3] clearly shows a highly significant
decrease in hazard of recurrence in patients treated with
chemotherapy in comparison with those who received no
chemotherapy (hazard ratio of 0.37; P < 0.001). This
confounding variable combined with the limited number of
samples tested makes the microarray results difficult to
interpret. Prospective studies that are much less sensitive to
these sources of bias should be the priority for future research.
Defined criteria and endpoints
However, it is vital that both prospective and retrospective
studies use clinically relevant criteria for categorising patients;
these should be clearly defined and prospectively applied.
Chang and colleagues [5] used median residual volume to
measure tumour response to docetaxel in a prospective study
of 24 patients with primary breast cancer, although
pathological response is known to be the most important
clinical outcome measure because it is strongly correlated
with survival [25]. van de Vijver and colleagues [3] classified
their breast cancers as positive or negative for oestrogen
receptor on the basis of the expression array values and not a
validated immunohistochemical test. This value was then
used inconsistently as a categorical variable for examining
association with the prognostic signature, and as a
continuous variable in multivariate analysis to examine the
independent effect of the signature on prognosis. Arbitrarily
defined outcome measures that do not represent established
clinical criteria are likely to increase subjective bias.
Statistical considerations
How can we decide whether a classifier might be a useful
clinical test? The performance of any test is dependent upon
the cut-off point used to discriminate between outcomes.
van ’t Veer and colleagues [2] and van de Vijver and
colleagues [3] claim a correct classification rate of 83% for
good prognosis. Similarly, Huang and colleagues [7] report a
90% accuracy for predicting outcome. However, these
results were based on arbitrarily defined cut-off values. As
these cut-off points were user defined they do not allow true
estimation of the predictive power of the classifier and the
use of differing values by van de Vijver and colleagues [3] is
inappropriate and confusing. A more robust estimate is
obtained by using sensitivity and specificity values obtained
at multiple cut-off points to draw a receiver operating
characteristics (ROC) curve. The area under the curve
(AUC) is the best estimate of the performance of a classifier
and this method was used by Chang and colleagues [5]: the
reported area under the curve for their classifier was 0.96
(range 0 to 1).
Even with robust technology and rigorous analysis, the major
challenge in the experimental design is the huge disproportion
between the number of variables tested (gene expression
values) and the number of samples. This inevitably leads to a
high false-discovery rate and over-fitting of statistical models to
the cohort under study (Fig. 1). It follows that appropriate
validation of the classifier is an essential requirement in
estimating the error of a classifier. Internal validation on the set
from which a classifier was generated is usually performed. This
is performed either by dividing the data into a test set (for
obtaining a classifier) and a training set (for estimating the
error) or by leaving one case out at a time, developing a model
from the remaining cases (training set) and testing it on the
omitted case (test set). In either method it is mandatory not to
include all cases for developing a classifier before testing it on
the training set because this results in overestimating the
accuracy of a classifier. van ’t Veer and colleagues [2]
performed an internal validation on their data set with
Figure 1
A simple case of over-fitting. Consider that a researcher is studying the
effect of TP53 expression level (x) on survival (y) of a group of breast
cancer patients. (a) Simple regression: from knowing the expression
level and survival (the variables) for each patient, the relationship
between the two variables can be modelled with a simple univariable
linear regression equation of the form y = a + bx, where a is the
interception point with the y axis and b is the slope of the equation line.
Applying this equation to a TP53 expression value will result in a new y
value that corresponds to predicted survival. However, the equation
seldom gives a perfect match between the real survival (triangles) and
the predicted survival from the equation (circles) for any given x. In
general, the closer the predicted values are to the real values, the
better the equation (model) is in explaining the observations or the
better the ‘fit’ of the model. The fit of the model is therefore used as a
measure of its performance. (b) Over-fitting: an equation that is
dependent on only two observations will always result in a line that
passes between these two observations, giving an artificially perfect
match between the predicted and the observed data. This represents
meaningless good performance of a model or ‘over-fitting’. This results
from using too few observations (patients) per variable (gene) studied.
To make a more complex ‘multi-variable analysis’ requires even more
observations (patients) required to avoid over-fitting. In practice, a
working ratio of 10 patients for every variable studied is recommended.
However, in microarray studies few patients are evaluated for many
thousands of genes.
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(improperly) and without (properly) this distinct separation
between training sets and test sets. The published sensitivity of
their classifier of 73% was obtained when the internal validation
was improperly done and only 59% when the validation was
properly done (published as supplementary material) [26,27].
Neither of the two types of internal validation is a substitute
for independent validation on different data sets. Only three
reports attempted such validation in breast cancer studies
[2,3,5]. van ’t Veer and colleagues [2] and Chang and
colleagues [5] performed only a limited validation on 15 and
6 patients, respectively. Although van de Vijver and
colleagues [3] reported a validation of the classifier of van ’t
Veer and colleagues [2] on 151 patients with lymph-node-
negative disease, 61 patients were in fact taken from the
original study. It is therefore unclear how applicable these
classifiers are to the wider population at risk.
Reproducible analysis
These criticisms underscore the importance of compre-
hensive reporting of the raw data so that results can be
compared and possibly validated with different studies. Sorlie
and colleagues [1] published both microarray image files as
well as individual feature intensity values, allowing full
reinterpretation of their data. This example has not been
followed by subsequent researchers. For example, van ’t Veer
and colleagues [2] merely reported average outcome
correlations for 232 genes of their classifier and not the
original raw data. Sotiriou and colleagues [6] identified 56
overlapping genes between their set of 485 differentially
expressed genes and those reported by van ’t Veer and
colleagues [2]. Because the raw data for all the genes in the
latter study are not available, it is difficult to exclude a random
effect as the cause of this overlap. In addition, most
descriptions of analysis methods in published papers are
inadequate (for example see [28]). Analysis tools such as the
open-source statistical language R and its microarray-specific
Bioconductor packages are essentially high-level program-
ming environments that oblige the user to enter declarations
and expressions to analyse data [29,30]. This type of
interaction makes it relatively easy to output detailed
transcripts that contain both commands and data, and
therefore allow reproducible analyses [31]. Analysis methods
based on using software with graphical user interfaces are
harder to record, but as a minimum, significant intermediate
calculations and data objects should be submitted as
supplementary information so that cross-checking by the
reader is possible. Finally, to make the best use of microarray
data sets, individual patient data should be anonymously
reported and electronically accessible. The use of controlled
vocabulary and standardised indices is critical for the reuse of
clinical information.
Conclusion
Microarray profiling has, unquestionably, been established as
a powerful tool in unravelling mechanistic insights into tumour
biology. We argue here that the optimum use of such a
technique in clinical studies requires the further optimisation
and standardisation of reporting procedures coupled with
carefully planned prospective studies. It is important to
underscore the difference between validating a classifier and
justifying its use in clinical practice. The latter requires
evidence of significant improvement of clinical outcome for
patients when a classifier is used to guide management. This
ultimately requires testing a classifier in a randomised
prospective trial to prove that a ‘classifier-informed’
management yields a better clinical outcome than a
‘classifier-blind’ arm. However, we argue that the data
produced so far may be too preliminary to launch large-scale
expensive phase III studies. Many of the methodological
problems in identifying prognostic factors are not new and
have been successively ignored by the clinical community
over the past 20 years. The great danger of using new
technology with newer problems is that these older lessons
are quickly forgotten.
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